Annual Accounts Receivable
$221.73 M
+$59.65 M+36.80%
December 31, 2024
Summary
- As of March 10, 2025, ANIP annual accounts receivable is $221.73 million, with the most recent change of +$59.65 million (+36.80%) on December 31, 2024.
- During the last 3 years, ANIP annual accounts receivable has risen by +$93.20 million (+72.51%).
- ANIP annual accounts receivable is now at all-time high.
Performance
ANIP Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$221.73 M
+$25.36 M+12.92%
December 31, 2024
Summary
- As of March 10, 2025, ANIP quarterly accounts receivable is $221.73 million, with the most recent change of +$25.36 million (+12.92%) on December 31, 2024.
- Over the past year, ANIP quarterly accounts receivable has increased by +$25.36 million (+12.92%).
- ANIP quarterly accounts receivable is now at all-time high.
Performance
ANIP Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
ANIP Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +36.8% | +12.9% |
| 3 y3 years | +72.5% | +12.9% |
| 5 y5 years | +207.4% | +12.9% |
ANIP Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +72.5% | at high | +72.5% |
| 5 y | 5-year | at high | +207.4% | at high | +207.4% |
| alltime | all time | at high | -100.0% | at high | -100.0% |
ANI Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $221.73 M(+36.8%) | $221.73 M(+12.9%) |
| Sep 2024 | - | $196.36 M(+18.2%) |
| Jun 2024 | - | $166.09 M(-3.7%) |
| Mar 2024 | - | $172.42 M(+6.4%) |
| Dec 2023 | $162.08 M(-2.0%) | $162.08 M(-9.4%) |
| Sep 2023 | - | $178.84 M(+3.4%) |
| Jun 2023 | - | $172.93 M(-1.0%) |
| Mar 2023 | - | $174.71 M(+5.6%) |
| Dec 2022 | $165.44 M(+28.7%) | $165.44 M(+17.8%) |
| Sep 2022 | - | $140.43 M(-6.6%) |
| Jun 2022 | - | $150.41 M(+14.3%) |
| Mar 2022 | - | $131.63 M(+2.4%) |
| Dec 2021 | $128.53 M(+34.2%) | $128.53 M(+20.4%) |
| Sep 2021 | - | $106.71 M(+15.2%) |
| Jun 2021 | - | $92.65 M(+0.8%) |
| Mar 2021 | - | $91.88 M(-4.1%) |
| Dec 2020 | $95.79 M(+32.8%) | $95.79 M(+14.4%) |
| Sep 2020 | - | $83.75 M(+14.5%) |
| Jun 2020 | - | $73.16 M(-11.2%) |
| Mar 2020 | - | $82.38 M(+14.2%) |
| Dec 2019 | $72.13 M(+11.2%) | $72.13 M(+2.0%) |
| Sep 2019 | - | $70.70 M(-7.3%) |
| Jun 2019 | - | $76.27 M(+13.1%) |
| Mar 2019 | - | $67.41 M(+4.0%) |
| Dec 2018 | $64.84 M(+10.3%) | $64.84 M(-4.1%) |
| Sep 2018 | - | $67.65 M(+20.6%) |
| Jun 2018 | - | $56.12 M(+2.4%) |
| Mar 2018 | - | $54.80 M(-6.8%) |
| Dec 2017 | $58.79 M(+28.1%) | $58.79 M(-5.4%) |
| Sep 2017 | - | $62.17 M(+12.0%) |
| Jun 2017 | - | $55.51 M(+18.9%) |
| Mar 2017 | - | $46.70 M(+1.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $45.90 M(+109.3%) | $45.90 M(-3.3%) |
| Sep 2016 | - | $47.48 M(+33.5%) |
| Jun 2016 | - | $35.56 M(+58.2%) |
| Mar 2016 | - | $22.48 M(+2.5%) |
| Dec 2015 | $21.93 M(+26.8%) | $21.93 M(+1.3%) |
| Sep 2015 | - | $21.64 M(+14.6%) |
| Jun 2015 | - | $18.88 M(+8.7%) |
| Mar 2015 | - | $17.37 M(+0.4%) |
| Dec 2014 | $17.30 M(+38.2%) | $17.30 M(+18.7%) |
| Sep 2014 | - | $14.57 M(+86.9%) |
| Jun 2014 | - | $7.79 M(-28.5%) |
| Mar 2014 | - | $10.91 M(-12.8%) |
| Dec 2013 | $12.51 M(>+9900.0%) | $12.51 M(+31.5%) |
| Sep 2013 | - | $9.52 M(+48.0%) |
| Jun 2013 | - | $6.43 M(>+9900.0%) |
| Dec 2010 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2010 | - | $0.00(-100.0%) |
| Jun 2010 | - | $53.20 K(-59.9%) |
| Mar 2010 | - | $132.70 K(+105.4%) |
| Dec 2009 | $64.60 K(-71.9%) | $64.60 K(+68.7%) |
| Sep 2009 | - | $38.30 K(-67.3%) |
| Jun 2009 | - | $117.30 K(-67.1%) |
| Mar 2009 | - | $356.80 K(+55.3%) |
| Dec 2008 | $229.80 K(+1474.0%) | $229.80 K(+178.5%) |
| Sep 2008 | - | $82.50 K(+287.3%) |
| Jun 2008 | - | $21.30 K(-29.5%) |
| Mar 2008 | - | $30.20 K(+106.8%) |
| Dec 2007 | $14.60 K(-99.9%) | $14.60 K(-99.6%) |
| Sep 2007 | - | $3.60 M(+0.6%) |
| Jun 2007 | - | $3.58 M(+1.8%) |
| Mar 2007 | - | $3.51 M(-66.6%) |
| Dec 2006 | $10.51 M | $10.51 M |
FAQ
- What is ANI Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals annual accounts receivable year-on-year change?
- What is ANI Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals quarterly accounts receivable year-on-year change?
What is ANI Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of ANIP is $221.73 M
What is the all time high annual accounts receivable for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high annual accounts receivable is $221.73 M
What is ANI Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, ANIP annual accounts receivable has changed by +$59.65 M (+36.80%)
What is ANI Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of ANIP is $221.73 M
What is the all time high quarterly accounts receivable for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high quarterly accounts receivable is $221.73 M
What is ANI Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, ANIP quarterly accounts receivable has changed by +$25.36 M (+12.92%)